[go: up one dir, main page]

WO2024155747A3 - Asgpr binding compounds and conjugates - Google Patents

Asgpr binding compounds and conjugates Download PDF

Info

Publication number
WO2024155747A3
WO2024155747A3 PCT/US2024/011898 US2024011898W WO2024155747A3 WO 2024155747 A3 WO2024155747 A3 WO 2024155747A3 US 2024011898 W US2024011898 W US 2024011898W WO 2024155747 A3 WO2024155747 A3 WO 2024155747A3
Authority
WO
WIPO (PCT)
Prior art keywords
conjugates
cell surface
asgpr
interest
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2024/011898
Other languages
French (fr)
Other versions
WO2024155747A2 (en
Inventor
Jason G. Lewis
Tao Chen
Darin Hildebrandt
Steven W. RANK
Eric D. Turtle
Shuai ZHENG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lycia Therapeutics Inc
Original Assignee
Lycia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lycia Therapeutics Inc filed Critical Lycia Therapeutics Inc
Priority to KR1020257026847A priority Critical patent/KR20250144397A/en
Priority to AU2024208960A priority patent/AU2024208960A1/en
Priority to CN202480015602.6A priority patent/CN120813382A/en
Priority to EP24705914.0A priority patent/EP4651902A2/en
Publication of WO2024155747A2 publication Critical patent/WO2024155747A2/en
Publication of WO2024155747A3 publication Critical patent/WO2024155747A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present disclosure provides a class of compounds including a ligand moiety that specifically binds to a cell surface asialoglycoprotein receptor (ASGPR). The cell surface ASGPR binding compounds can trigger the receptor to internalize into the cell a bound compound. The ligand moieties of this disclosure can be linked to a variety of moieties of interest without impacting the specific binding to, and function of, the cell surface receptor ASGPR. Also provided are compounds that are conjugates of the ligand moieties linked to a biomolecule, such as an antibody, which conjugates can harness cellular pathways to remove specific proteins of interest from the cell surface or from the extracellular milieu. Also provided herein are methods of using the conjugates to target a polypeptide of interest for sequestration and/or lysosomal degradation.
PCT/US2024/011898 2023-01-18 2024-01-17 Asgpr binding compounds and conjugates Ceased WO2024155747A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
KR1020257026847A KR20250144397A (en) 2023-01-18 2024-01-17 ASGPR binding compounds and conjugates
AU2024208960A AU2024208960A1 (en) 2023-01-18 2024-01-17 Asgpr binding compounds and conjugates
CN202480015602.6A CN120813382A (en) 2023-01-18 2024-01-17 ASGPR binding compounds and conjugates
EP24705914.0A EP4651902A2 (en) 2023-01-18 2024-01-17 Asgpr binding compounds and conjugates

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202363439811P 2023-01-18 2023-01-18
US63/439,811 2023-01-18
US202363518532P 2023-08-09 2023-08-09
US63/518,532 2023-08-09

Publications (2)

Publication Number Publication Date
WO2024155747A2 WO2024155747A2 (en) 2024-07-25
WO2024155747A3 true WO2024155747A3 (en) 2024-08-22

Family

ID=89977409

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/011898 Ceased WO2024155747A2 (en) 2023-01-18 2024-01-17 Asgpr binding compounds and conjugates

Country Status (5)

Country Link
EP (1) EP4651902A2 (en)
KR (1) KR20250144397A (en)
CN (1) CN120813382A (en)
AU (1) AU2024208960A1 (en)
WO (1) WO2024155747A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202516008A (en) * 2023-09-27 2025-04-16 大陸商上海拓界生物醫藥科技有限公司 Triazolyl-containing compounds, preparation method thereof and use thereof
WO2025143096A1 (en) * 2023-12-29 2025-07-03 キッセイ薬品工業株式会社 Nitrogen-containing condensed ring compound

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021142377A2 (en) * 2020-01-10 2021-07-15 Lycia Therapeutics, Inc. Cell surface receptor binding compounds and conjugates
WO2021155317A1 (en) * 2020-01-31 2021-08-05 Avilar Therapeutics, Inc. Asgpr-binding compounds for the degradation of extracellular proteins
WO2023288033A1 (en) * 2021-07-14 2023-01-19 Lycia Therapeutics, Inc. Asgpr cell surface receptor binding compounds and conjugates

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005538706A (en) 2001-07-12 2005-12-22 ジェファーソン フーテ， Super humanized antibody
EP3088004B1 (en) 2004-09-23 2018-03-28 Genentech, Inc. Cysteine engineered antibodies and conjugates
EP4640239A2 (en) 2014-03-19 2025-10-29 Genzyme Corporation Site-specific glycoengineering of targeting moieties
CA3205824A1 (en) 2014-10-09 2016-04-14 Genzyme Corporation Glycoengineered antibody drug conjugates

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021142377A2 (en) * 2020-01-10 2021-07-15 Lycia Therapeutics, Inc. Cell surface receptor binding compounds and conjugates
WO2021155317A1 (en) * 2020-01-31 2021-08-05 Avilar Therapeutics, Inc. Asgpr-binding compounds for the degradation of extracellular proteins
WO2023288033A1 (en) * 2021-07-14 2023-01-19 Lycia Therapeutics, Inc. Asgpr cell surface receptor binding compounds and conjugates

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GALINA S. RESHITKO: "Synthesis and Evaluation of New Trivalent Ligands for Hepatocyte Targeting via the Asialoglycoprotein Receptor", BIOCONJUGATE CHEMISTRY, vol. 31, no. 5, 7 May 2020 (2020-05-07), US, pages 1313 - 1319, XP093161812, ISSN: 1043-1802, DOI: 10.1021/acs.bioconjchem.0c00202 *

Also Published As

Publication number Publication date
WO2024155747A2 (en) 2024-07-25
CN120813382A (en) 2025-10-17
EP4651902A2 (en) 2025-11-26
KR20250144397A (en) 2025-10-10
AU2024208960A1 (en) 2025-07-24

Similar Documents

Publication Publication Date Title
WO2021142377A3 (en) Cell surface receptor binding compounds and conjugates
WO2023288033A8 (en) Asgpr cell surface receptor binding compounds and conjugates
WO2024155747A3 (en) Asgpr binding compounds and conjugates
WO2022150721A9 (en) Bifunctional folate receptor binding compounds
NO20080970L (en) Glycopegylated factor VII and factor VIIA
WO2006127910A3 (en) Glycopegylated erythropoietin formulations
JP2015529208A5 (en)
WO2009100194A3 (en) Camptothecin-binding moiety conjugates
WO2006127896A3 (en) Glycopegylated factor ix
WO2007027713A3 (en) Trail receptor 2 polypeptides and antibodies
WO2006074467A3 (en) Glycopegylated granulocyte colony stimulating factor
WO2007108013A3 (en) Novel bioconjugates as therapeutic agent and synthesis thereof
NZ598401A (en) Conjugates of pyrrolo[1,4]benzodiazepine dimers as anticancer agents
WO2007000343A3 (en) Process for manufacturing vaccines
WO2008000517A3 (en) Conjugates for innate immunotherapy of cancer
WO2008063721A3 (en) Luminescent macrocyclic lanthanide complexes
WO2009139863A3 (en) Chimeric small molecules for the recruitment of antibodies to cancer cells
WO2008088658A3 (en) Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
WO2008063902A3 (en) Biofunctional materials
WO2007094842A3 (en) Binding polypeptides and uses thereof
RU2013119960A (en) AMATOXIN CONJUGATES WITH IMPROVED LINKERS
WO2006050262A3 (en) Compositions and methods for modification of biomolecules
WO2007028118A3 (en) Nicotinic acid and picolinic acid derived near-infrared fluorophores
EP2660247A3 (en) High penetration prodrug compositions of peptides and peptide-related compounds
WO2009010976A3 (en) Compositions and methods for purifying and crystallizing molecules of interest

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24705914

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: AU2024208960

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2025541057

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2024208960

Country of ref document: AU

Date of ref document: 20240117

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 1020257026847

Country of ref document: KR

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A15-NAP-PA0105 (AS PROVIDED BY THE NATIONAL OFFICE)

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 202480015602.6

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020257026847

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 202480015602.6

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2024705914

Country of ref document: EP